CORPORATE MEDIA RELEASE
NORGINE OPENS ITS NEW GERMAN OFFICES IN WETTENBERG
Norgine continues its investment to underpin its growth strategy
Germany is the largest product sales market for Norgine
AMSTERDAM. The Netherlands, Friday 20 July 2018, 15:30 CET. Norgine B.V. today announced that it has opened new offices in Germany, Im Westpark 14 35435, Wettenberg, Germany.
Norgine is a leading European specialist pharma company which has been established for over 110 years with headquarters in the Netherlands. Norgine acquires, develops, manufactures and commercialises transformative products meeting patients’ needs in specialist therapy areas – gastroenterology, hepatology, cancer and supportive care, and a portfolio of well established brands.
Norgine has been established in Germany since 1928 and employs over 100 staff in commercial, development and other support functions. Norgine’s key leading products in Germany are – PLENVU®, XIFAXAN®, MOVICOL®, MOVIPREP®, LYMPHOSEEK® and DANTRIUM®.
Peter Stein, CEO of Norgine said: “We are confident that our new offices in Germany will help us to maintain the supply of our transformative products and high quality service to healthcare organisations and patients. We believe that this investment will continue to support our strong “One Norgine” team who share, with our partners a vision for improving patients’ lives.”
The office was officially opened by Peter Stein and was attended by the Head of the Chancellery and Federal Minister for Special Affairs, Prof. Dr. Helge Braun and Mr Thomas Brunner, Mayor of Wettenberg.
Norgine German office in Wettenberg
Peter Stein, CEO Norgine
Kenneth MacRitchie, Interim General Manager of Norgine Germany
Dr. Helge Braun, the Head of the Chancellery and Federal Minister for Special Affairs
Mr Thomas Brunner, Mayor of Wettenberg
For further information on Norgine Germany, please go to www.norgine.de
Notes to Editors:
About Norgine
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.
Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
Media Contacts:
Isabelle Jouin, T: +44 (0)1895 453643
Follow us @norgine
Sitios web de Norgine
Contáctenos